Ann: March 2022 Quarterly Activities Report and Appendix 4C, page-8

The most positive news from todays announcement is the CEP trial the following words in the announcement . This is a valuable and rarely
awarded designation; last year only four Australian companies achieved this status.
ODD status is only granted to drugs that show promise for safe and effective treatment of diseases. Tells me that it works and if you look at the CEP1 trial results on Noxopharm website which is as follows

CEP-1

Phase-1 multi-centre study – complete

CEP-1 delivers proof-of-concept with Veyonda^® + chemotherapy

CEP-1 was a two-part study:

• In part 1 Veyonda^® (400 or 800 mg) was administered alone
• In part 2 Veyonda^® was administered in combination with carboplatin.

Of the 9 patients allocated to the higher dosage (800 mg) of Veyonda^®, 5/9 (56%) showed stable disease (no tumour growth and no new tumours) or a partial response (up to 99% shrinkage of measurable lesions) over the 8-month term of the study.

The Company and its medical advisors regard this outcome as significant, given that all patients had received considerable prior treatment and their cancer was classified as extensive and progressive Stage 4 chemotherapy-resistant disease.

Findings from this study have been published in the independent peer-reviewed Journal Current Therapeutic Research in 2021.